Peringkat dalam Saham
#6594
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to... GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Kapitalisasi Pasar
$1.96B
Perubahan (1 hari)
-1.65%
Perubahan (1 tahun)
109.32%
Perdagangan GH Research PLC (GHRS)
Harga GHRS dengan kapitalisasi pasar B
Kapitalisasi pasar dari GH Research PLC(GHRS)
Kapitalisasi Pasar: $1.96B
Per August 2026, GH Research PLC memiliki kapitalisasi pasar sebesar $1.96B. Ini menjadikan GH Research PLC sebagai perusahaan 6594th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar GH Research PLC dari 2021 hingga 2026
GHRS dibandingkan dengan 5 teratas stocks paling populer
| Harga GHRS |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.532T
|
+282,710.35%
|
|
|
|
|
$4.608T
|
+235,498.50%
|
|
|
|
|
$4.096T
|
+209,294.51%
|
|
|
|
|
$3.748T
|
+191,543.07%
|
|
|
|
|
$2.761T
|
+141,077.90%
|
